The non-recurrence rate of the IAD group and the CAD group with PSA ≤ 0.01 ng/ml.

<p>Kaplan-Meier analysis of progression-free survival in the patients who showed a PSA nadir of less than 0.01 ng/ml after LHRHa administration.</p

The median duration of time on treatment or time off treatment in the IAD group.

<p>The median duration of time on treatment or time off treatment in the IAD group.</p

Mean PSA level prior to posterior LHRHa therapy in the IAD group.

<p>Mean PSA level prior to posterior LHRHa therapy in the IAD group.</p

The non-recurrence rate and survival rate of the IAD group and the CAD group with Gleason Score ≤ 7.

<p>Kaplan-Meier analysis of progression-free survival (A) and overall survival (B) in both two groups in patients with Gleason Score ≤ 7.</p

Characteristics of patients treated with IAD and CAD.

<p>Characteristics of patients treated with IAD and CAD.</p

The non-recurrence rate and survival rate of the IAD group and the CAD group.

<p>Kaplan-Meier analysis of progression-free survival (A) and overall survival (B) in the IAD group and CAD group.</p